Entera Bio

Entera Bio EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Entera Bio (ENTX) as of Nov 22, 2026 is 1,141.72. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 255.15 — a change of 347.47% (higher).

EV/Revenue

1,141.72

YoY

347.47%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Entera Bio is 2025 1,141.72 . EV/Revenue (Enterprise Value to Revenue) of Entera Bio was 2024 255.15 . It decreases by 347.47% higher compared to the previous year.

The Entera Bio EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2018
86.10 USD
Jan 1, 2019
168.00 USD
Jan 1, 2020
127.15 USD
Jan 1, 2021
52.50 USD
Jan 1, 2022
316.06 USD
Jan 1, 2023
3,138.65 USD
Jan 1, 2024
255.15 USD
Jan 1, 2025
1,141.72 USD
The Entera Bio EV/Revenue history
YEAREV/RevenueYoY
1,141.72+347.47%
255.15-91.87%
3,138.65+893.05%
316.06+501.97%
52.50-58.71%
127.15-24.31%
168.00+95.12%
86.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

EV/Revenue (Enterprise Value to Revenue) of Entera Bio is 1,141.72 in 2025.

EV/Revenue (Enterprise Value to Revenue) of Entera Bio changed from 255.15 to 1,141.72, representing a 347.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Entera Bio since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Entera Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Entera Bio

All Key Metrics — Entera Bio